Meeting
2014 ASCO Annual Meeting
Phase lb study of LEE011 and BYL719 in combination with letrozole in estrogen receptor-positive, HER2-negative breast cancer (ER+, HER2− BC).
Authors
Pamela N. Munster
UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA
Pamela N. Munster , Erika Paige Hamilton , Catherine Franklin , Suraj Bhansali , Kitty Wan , Becker Hewes , Dejan Juric
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Highlights Session
Session Title
Breast Cancer - HER2/ER
Track
Breast Cancer
Sub Track
ER+
Clinical Trial Registration Number
NCT01872260
Citation
J Clin Oncol 32:5s, 2014 (suppl; abstr 533)
DOI
10.1200/jco.2014.32.15_suppl.533
Abstract #
533
Poster Bd #
23
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Clinico-molecular characteristics associated with outcomes in breast cancer patients treated with CDK4/6 inhibitors: Results from the AURORA Molecular Screening Initiative.
First Author: Elisa Agostinetto
Poster
2014 Breast Cancer Symposium
Ph IB study of LEE011 and BYL719 in combination with letrozole in ER+, HER2- breast cancer.
First Author: Pamela N. Munster
Poster
2023 ASCO Annual Meeting
First-in-human first-in-class phase 1/2a study of the next generation CDK4-selective inhibitor PF-07220060 in patients (pts) with advanced solid tumors, enriched for HR+ HER2- mBC who progressed on prior CDK4/6 inhibitors and endocrine therapy.
First Author: Timothy A. Yap
Poster
2023 ASCO Annual Meeting
A phase 3 study of gedatolisib plus fulvestrant with and without palbociclib in patients with HR+/ HER2- advanced breast cancer previously treated with a CDK4/6 inhibitor plus a nonsteroidal aromatase inhibitor (VIKTORIA-1).
First Author: Sara A. Hurvitz